Pharmaceuticals giant Bristol-Myers reported third-quarter results Thursday morning that beat analysts' expectations on both the top and bottom lines. So why did shares trade lower?
Paul Ausick Health care is one sector that continues to draw a ton of fund manager interest, and with good reason. These five dividend-paying health care stocks are all favored by large-cap portfolio managers.
MyoKardia shares hit an all-time high early on Monday after it was announced that Bristol-Myers Squibb would be acquiring the company.
Chris Lange Tuesday's top analyst upgrades and downgrades included AbbVie, CSX, Dominion Energy, JPMorgan, NXP Semiconductors, ONEOK, Pfizer, Square, United Parcel Service and WPX Energy.
What may make sense now is for nervous investors to hunker down in safe dividend-paying stocks of companies with products that will not go out of demand, at least until the election…
Tuesday’s top analyst upgrades and downgrades included Alibaba, Amazon.com, Apple, Carvana, Illumina, NextEra Energy, Nikola, Shake Shack, Teladoc Health and WPX Energy.
These five dividend-paying large-cap pharmaceutical stocks look like outstanding ideas for nervous investors looking for income and a degree of safety. They have come way in from their 52-week trading highs and…
With the market showing the potential for some sizable rotation, the research team at BofA Securities has added Medtronic to the firm's US 1 List of top stocks to buy. It and…
It is pretty clear that a defensive rotation already has started, and investors may want to consider rotating to these five top stocks from the overbought and very pricey tech sector.
This is a preview of a few of the most anticipated quarterly reports due this week, including CVS Health, Uber and Walt Disney.
Tuesday's top analyst upgrades and downgrades included ADM, Beyond Meat, Bristol-Myers, Carvana, CRISPR, FirstEnergy, Peloton, Shopify, Tesla, Uber and Visa.
The coming earnings data will be horrific, and the domestic and geopolitical scene is messy, so rotating to dividend-paying stocks that offer better upside and total return potential might be a very…
The April 15 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
The analysts at BofA Securities have made a big move by removing a high-profile company from the firm's well-respected US 1 list of stocks to buy. Some other picks look especially intriguing…
Exelixis stock jumped early on Monday after the company, in conjunction with Bristol-Myers Squibb, announced positive late-stage results from its kidney cancer study.
